<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957655</url>
  </required_header>
  <id_info>
    <org_study_id>SHED01</org_study_id>
    <nct_id>NCT03957655</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SHED for Decompensated Liver Cirrhosis</brief_title>
  <official_title>Safety and Efficacy of Stem Cells From Human Exfoliated Deciduous Teeth for Treatment of Decompensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAR-T (Shanghai) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an prospective, randomized control study. Patients with decompensated cirrhosis
      will be randomly assigned to receive 4 times of SHED treatment plus standard medical
      care(treatment）or standard medical care (control). The primary outcome is MELD-Na score.
      Secondary outcomes are Child-Pugh, liver function, life quality and survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, there is still no effective treatment for liver cirrhosis, and the use of stem
      cells for the treatment of cirrhosis has caused great concern.Stem cells from human
      exfoliated deciduous teeth (SHED) has been shown to be safe and effective for liver diseases.
      Randomization controlled studies are needed to confirm the long term effect of SHED treatment
      for liver cirrhosis. The present study aimed to investigate the safety and efficacy of SHED
      in hepatitis B related liver cirrhosis patients.

      This study is an prospective, randomized control study. Patients with decompensated cirrhosis
      will be randomly assigned to receive 4 times of SHED treatment plus standard medical
      care(treatment）or standard medical care (control). SHED infusion (1x10E6 cells/kg body
      weight) via peripheral vein will be given at week 0,4,8,12.The primary outcome is MELD-Na
      score. Secondary outcomes are Child-Pugh, liver function, life quality and survival.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessors will be blind to the randomization results of the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Model for End-Stage Liver Disease (MELD)-Na score</measure>
    <time_frame>baseline and 4,8,12,16,24 week</time_frame>
    <description>The MELD-Na score is a reliable measure of mortality risk in patients with end-stage liver disease.
MELD-Na score=3.8ln[bilirubin (mg/dl)]+11.21ln(INR) +9.6ln[creatinine (mg/dl) +6.4* (cause: cholestasis and alcoholic cirrhosis are 0, others are 1) +1.59* (135-Na)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child-Pugh score</measure>
    <time_frame>baseline and 4,8,12,16,24 week</time_frame>
    <description>The Child-Pugh score is a scoring system to measure the severity of chronic liver disease inclusive of cirrhosis. The point scores are added up and classified as: class A: 5-6 points class B: 7-9 points class C: 10-15 points
The score is composed from several categories:
total bilirubin, μmol/l (mg/dl)&lt;34: 1 point 34-50: 2 points &gt;50: 3 points
serum albumin, g/l&gt;35: 1 point 28-35: 2 points &lt;28: 3 points
INR&lt;1.7: 1 point 1.7-2.3: 2 points &gt;2.3: 3 points
presence of ascites none: 1 point mild: 2 points moderate to severe: 3 points
presence of hepatic encephalopathy none: 1 point grades I-II : 2 point grades III-IV: 3 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of liver function</measure>
    <time_frame>baseline and 4,8,12,16,24 week</time_frame>
    <description>Changes of liver function index such as ALT, AST, ALB, TBIL, PT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of life quality</measure>
    <time_frame>baseline and 4,8,12,16,24 week</time_frame>
    <description>Changes of life quality as assessed by SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Rate at half of one year</measure>
    <time_frame>half of one year</time_frame>
    <description>Survival rate at half of one year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>SHED group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHED transplantation via peripheral vein: 1x10E6 SHEDs/kg body weight administered via peripheral vein at week 0,4,8,12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard medication for viral hepatitis and cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SHED group</intervention_name>
    <description>1x10E6 MSCs/kg body weight will be administered via peripheral vein for 4 times at week 0,4,8,12</description>
    <arm_group_label>SHED group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-70 years

          2. HBV-related liver cirrhosis with presentations of decompensation

          3. Antiviral treatment with nucleotide drugs for more than half a year and HBV DNA is
             less than the minimum detection limit;

          4. Child-Pugh score B and MELD-Na score≤25

          5. Written consent

        Exclusion Criteria:

          1. Hepatic encephalopathy, hepatorenal syndrome, acute phase of severe hepatitis

          2. Child-Pugh score A or C

          3. Hepatocellular carcinoma or other malignancies

          4. Cirrhosis or liver failure caused by non-Hepatitis B

          5. Pregnancy or breastfeeding

          6. Severe bacteria infection,coinfection with HIV or other viral hepatitis.

          7. History of severe allergy to biological products or history of immunization within
             half a year

          8. Patients or family members refused to participate in the study

          9. Drug abuse or alcohol abuse

         10. Other candidates who are judged to be not applicable to this study by doctors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Li, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chengzhong Li, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lei Xin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianya Xue, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Xin, Dr.</last_name>
    <phone>862131161365</phone>
    <email>aip_xin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lei Xin, Dr.</last_name>
      <phone>862131161365</phone>
      <email>aip_xin@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianya Xue, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lei Xin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang D, Zhang H, Liang J, Wang H, Hua B, Feng X, Gilkeson GS, Farge D, Shi S, Sun L. A Long-Term Follow-Up Study of Allogeneic Mesenchymal Stem/Stromal Cell Transplantation in Patients with Drug-Resistant Systemic Lupus Erythematosus. Stem Cell Reports. 2018 Mar 13;10(3):933-941. doi: 10.1016/j.stemcr.2018.01.029. Epub 2018 Mar 1.</citation>
    <PMID>29478901</PMID>
  </reference>
  <reference>
    <citation>Xuan K, Li B, Guo H, Sun W, Kou X, He X, Zhang Y, Sun J, Liu A, Liao L, Liu S, Liu W, Hu C, Shi S, Jin Y. Deciduous autologous tooth stem cells regenerate dental pulp after implantation into injured teeth. Sci Transl Med. 2018 Aug 22;10(455). pii: eaaf3227. doi: 10.1126/scitranslmed.aaf3227.</citation>
    <PMID>30135248</PMID>
  </reference>
  <reference>
    <citation>Ohkoshi S, Hara H, Hirono H, Watanabe K, Hasegawa K. Regenerative medicine using dental pulp stem cells for liver diseases. World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):1-6. doi: 10.4292/wjgpt.v8.i1.1.</citation>
    <PMID>28217369</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 19, 2019</study_first_submitted>
  <study_first_submitted_qc>May 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>stem cell</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

